CerS2 Is a Druggable Target in Triple-Negative Breast Cancer.

Alatawi H, Nair HH, Ai L, Mahmud I, Gour A, Singh A, Baek D, Yan B, Maharjan CK, Zhang W, Law BK, Zajac-Kaye M, Vulpe C, Guryanova OA, Sharma AK, Garrett TJ, Sharma A, Heldermon CD, Hong S, Narayan S

Open source

DOI: 10.1158/1535-7163.mct-25-1159
Published: 2026 Jul 2
Container: Molecular cancer therapeutics
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1535-7163.mct-25-1159,
  title = {CerS2 Is a Druggable Target in Triple-Negative Breast Cancer.},
  author = {Alatawi H and Nair HH and Ai L and Mahmud I and Gour A and Singh A and Baek D and Yan B and Maharjan CK and Zhang W and Law BK and Zajac-Kaye M and Vulpe C and Guryanova OA and Sharma AK and Garrett TJ and Sharma A and Heldermon CD and Hong S and Narayan S},
  year = {2026},
  journal = {Molecular cancer therapeutics},
  doi = {10.1158/1535-7163.mct-25-1159},
  url = {https://doi.org/10.1158/1535-7163.mct-25-1159}
}

RIS

TY  - JOUR
TI  - CerS2 Is a Druggable Target in Triple-Negative Breast Cancer.
AU  - Alatawi H
AU  - Nair HH
AU  - Ai L
AU  - Mahmud I
AU  - Gour A
AU  - Singh A
AU  - Baek D
AU  - Yan B
AU  - Maharjan CK
AU  - Zhang W
AU  - Law BK
AU  - Zajac-Kaye M
AU  - Vulpe C
AU  - Guryanova OA
AU  - Sharma AK
AU  - Garrett TJ
AU  - Sharma A
AU  - Heldermon CD
AU  - Hong S
AU  - Narayan S
PY  - 2026
JO  - Molecular cancer therapeutics
DO  - 10.1158/1535-7163.mct-25-1159
UR  - https://doi.org/10.1158/1535-7163.mct-25-1159
ER  -

APA

H, A., HH, N., L, A., I, M., A, G., A, S., D, B., B, Y., CK, M., W, Z., BK, L., M, Z., C, V., OA, G., AK, S., TJ, G., A, S., CD, H., S, H., & S, N. (2026). CerS2 Is a Druggable Target in Triple-Negative Breast Cancer.. Molecular cancer therapeutics. https://doi.org/10.1158/1535-7163.mct-25-1159

Source records

pubmed · retrieved 2026-09-26T07:47:26.393Z
europe-pmc · retrieved 2026-09-26T07:47:26.412Z